Compare OMEX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | STTK |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.8M | 119.0M |
| IPO Year | N/A | 2020 |
| Metric | OMEX | STTK |
|---|---|---|
| Price | $2.24 | $3.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 848.5K | 429.0K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $467,122.00 | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.69 |
| 52 Week High | $4.43 | $3.38 |
| Indicator | OMEX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 72.56 |
| Support Level | $2.17 | $2.82 |
| Resistance Level | $2.36 | $3.29 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 18.37 | 93.75 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. The company provides specialized mineral exploration, project development, and marine services to clients. It is engaged in the discovery, validation, and development of subsea mineral deposits in a socially and environmentally responsible manner. The company works with governments to identify mineral resources in Exclusive Economic Zones, focusing on phosphorite (fertilizer) and polymetallic nodules (battery metals) projects. Its projects include the ExO Phosphate project, CIC, Ocean Minerals, and the LIHIR Gold project.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.